IMNN Share Price Performance
US$2.55
-4.78 (-65.19%)
88.1% undervalued intrinsic discount
US$21.50
Fair Value
Price US$2.55
AnalystConsensusTarget US$21.50
AnalystHighTarget US$33.00
Fair ValueUS$21.50
Share Pricen/a
Imunon, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
IMNN Community Narratives
AN
Fair Value
·Fair Value US$21.5 88.1% undervalued intrinsic discount
Phase III Ovarian Cancer Trial And IL-12 Focus Will Reshape This Long-Term Thesis
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$33 92.3% undervalued intrinsic discount
Frontline Ovarian Cancer Trial Success Will Transform Long Term Potential For This IL 12 Therapy
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Frontline Ovarian Cancer Trial Success Will Transform Long Term Potential For This IL 12 Therapy
Catalysts About Imunon Imunon is a clinical stage biotechnology company focused on developing IMNN-001, an IL-12 based immunotherapy for women with newly diagnosed advanced ovarian cancer. What are the underlying business or industry changes driving this perspective?Read more
AN
US$33
92.3% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
32.22x
Price in 2029
US$0
Phase III Ovarian Cancer Trial And IL-12 Focus Will Reshape This Long-Term Thesis
Catalysts About Imunon Imunon is a clinical stage biotechnology company developing IMNN-001, an intraperitoneal IL-12 based immunotherapy for women with newly diagnosed advanced ovarian cancer. What are the underlying business or industry changes driving this perspective?Read more
AN
US$21.5
88.1% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
106.03x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Frontline Ovarian Cancer Trial Success Will Transform Long Term Potential For This IL 12 Therapy
Fair Value: US$33 92.3% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Phase III Ovarian Cancer Trial And IL-12 Focus Will Reshape This Long-Term Thesis
Fair Value: US$21.5 88.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Imunon, Inc. Key Details
About IMNN
- Founded
- 1982
- Employees
- 25
- CEO
- WebsiteView website
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
